A case-control study of HIV seroconversion in health care workers after percutaneous exposure

New England Journal of Medicine

Volumn 337, Issue 21, 1997, Pages 1485-1490

  Cardo, Denise M ^a,g   Culver, David H ^a   Ciesielski, Carol A ^b   Srivastava, Pamela U ^a   Marcus, Ruthanne ^a   Abiteboul, Dominique ^c   Heptonstall, Julia ^d   Ippolito, Giuseppe ^e   Lot, Florence ^f   McKibben, Penny S ^a   Bell, David M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUT NATIONAL DE RECHERCHE ET DE SÉCURITÉ   (France)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Ctro Riferimento AIDS C   (Italy)

^f Reseau National de Sante Publique   (France)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; NEEDLESTICK INJURY; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SEROCONVERSION;

ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; BLOOD-BORNE PATHOGENS; CASE-CONTROL STUDIES; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; FEMALE; HEALTH PERSONNEL; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; MALE; NEEDLESTICK INJURIES; OCCUPATIONAL DISEASES; POPULATION SURVEILLANCE; RISK FACTORS; WOUNDS, STAB; ZIDOVUDINE;

EID: 0030692781     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711203372101     Document Type: Article

References (26)

1. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913-9.
2. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: a prospective evaluation. Ann Intern Med 1990;113: 740-6.
3. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1994;170:1410-7
4. Ippolito G, Puro V, De Carli G, Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus infection in health care workers: Italian Multicenter Study. Arch Intern Med 1993;153:1451-8.
5. LaFon SW, Mooney BD, McMullen JP, et al. A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine, ZDV) as a chemoprophylactic agent in health care workers (HCW) exposed to HIV. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21-24, 1990. Washington, D.C.: American Society for Microbiology, 1990:167.
6. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep 1995;44:929-33.
7. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321: 1621-5.
8. Richman DD, Bozzette S. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
9. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
10. Sperling RS, Shapiro DE, Coombs R, et al. Maternal viral load, zidovudine treatment, and risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
11. Black R. Animal studies of prophylaxis. Am J Med 1997;102(5B):5B-39S-5B-44S.
12. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-9.
13. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13. [Erratum, N Engl J Med 1995;333:1367]
14. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 1996;271:1582-6.
15. Jochimsen EM. Failure of zidovudine postexposure prophylaxis. Am J Med 1997;102(5B):5B-52S-5B-55S.
16. Weisburd G, Biglione J, Arbulu MM, Tcrrazino JC, Pesiri A. HIV seroconversion after a work place accident and treated with zidovudine. In: Program and abstracts of the 11th International Conference on AIDS, Vancouver, B.C., July 7-12, 1996:460. abstract.
17. Lot F, Abiteboul D. Infections professionnelles par le V.I.H. en France: le point au 30 juin 1995. Bull Epidemiol Hebd 1995;44:193-4.
18. Chamberland ME, Bell DM. Human immunodeficiency virus infection. In: Bennett JV, Brachman PS, eds. Hospital infections. 4th ed. Boston: Little, Brown (in press).
19. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996;45:468-80.
20. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
21. Bell DM, Gerberding JM, eds. Human immunodeficiency virus (HIV) postexposure management of health care workers. Am J Med 1997; 102(5B):5B-1S-5B-126S.
22. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Morb Mortal Wkly Rep 1990; 39(RR-1):1-14.
23. Gerberding JL. Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Am J Med 1997;102(5B):5B-85S-5B-89S.
24. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;336:1097-100.
25. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR Morb Mortal Wkly Rep 1991;40(RR-8):1-9.
26. Bell DM, Shapiro CN, Culver DH, Martone WJ, Curran JW, Hughes JM. Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model. Infect Agents Dis 1992; 1:263-9.